Laura Svajda

Budapest, BU 1037, Hungary

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Importance of Patient-Derived Xenograft Models in Battling Cancer Therapy Resistance.

Importance of Patient-Derived Xenograft Models in Battling Cancer Therapy Resistance.

Journal: Cancers
Published: May 05, 2026

Targeting tumor hypoxia in combined therapeutic strategies in breast and ovarian cancer

Targeting tumor hypoxia in combined therapeutic strategies in breast and ovarian cancer

Journal: Magyar onkologia
Published: January 12, 2026

Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer.

Targeting hypoxia in combination with paclitaxel to enhance therapeutic efficacy in breast and ovarian cancer.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 11, 2024

Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1

Immunomodulation in the tumor microenvironment: Therapeutic potential of combined inhibition of tumor hypoxia and PD-1/ PD-L1

Journal: Magyar onkologia
Published: May 08, 2024

Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma.

Differential effects of hypoxia on motility using various in vitro models of lung adenocarcinoma.

Journal: Scientific reports
Published: February 20, 2024

CDK9 inhibition as an effective therapy for small cell lung cancer.

CDK9 inhibition as an effective therapy for small cell lung cancer.

Journal: Cell death & disease
Published: November 13, 2023

Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker.

Optimizing the enzymatic release of MMAE from isoDGR-based small molecule drug conjugate by incorporation of a GPLG-PABC enzymatically cleavable linker.

Journal: Frontiers in pharmacology
Published: May 02, 2023

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

EGFR R521K Polymorphism Is Not a Major Determinant of Clinical Cetuximab Resistance in Head and Neck Cancer.

Journal: Cancers
Published: March 25, 2022
Showing 1-8 of 8

Last Updated: 09/26/2026